ArticleBMC infectious diseases2025
Prognosis of patients with a history of organ transplantation during active COVID-19 infection.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities greatly increase the risk of severe illness and death. Despite global advances in vaccination and treatment, practical tools for early risk assessment in this group are still limited. This study aims to address this gap by identifying simple, widely available laboratory markers that can be used upon hospital admission to predict short-term outcomes in COVID-19 patients with a history of organ transplantation.
methodsWe retrospectively analyzed a cohort of solid organ transplant recipients hospitalized with confirmed COVID-19 infection at the University Clinical Center in Gdańsk, Poland, between 2020 and 2022. Patients were admitted to either a general COVID-19 ward or an intensive care unit based on disease severity. Data were collected from electronic medical records and included demographic characteristics, chest imaging, and routine laboratory tests: lymphocyte count, serum creatinine, aspartate aminotransferase, C-reactive protein, and procalcitonin. Statistical analyses were performed to evaluate the association of these variables with in-hospital mortality.
resultsOur analysis identified that elevated levels of serum creatinine, aspartate aminotransferase, C-reactive protein, and procalcitonin were significantly associated with increased risk of in-hospital mortality. Conversely, a higher lymphocyte count at admission was associated with better survival. These markers are widely available, inexpensive, and can be assessed during the initial diagnostic workup.
conclusionsThis study offers a practical, evidence-based approach to early risk stratification in transplant recipients with COVID-19. The identified laboratory markers are not only simple and accessible but also clinically meaningful, providing frontline clinicians with actionable information during the early stages of care. In light of the continued presence of COVID-19 and the likelihood of future viral outbreaks, these findings have broad implications for the management of immunosuppressed patients. The study provides valuable insights into a currently underserved area of transplant medicine and has strong potential to inform clinical practice across diverse healthcare settings.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.